Search This Blog

Monday, March 9, 2026

AtaiBeckley confirms Q2 2026 Phase 3 BPL-003 trials in treatment-resistant depression

 

AtaiBeckley posts Q4 2025 non-GAAP EPS -$1.73, revenue $1.1M, and confirms Q2 2026 Phase 3 BPL-003 trials in treatment-resistant depression

  • Non-GAAP EPS -$1.73 declined 621% YoY, missing analyst EPS estimates for fiscal Q4 2025.
  • Revenue $1.1M decreased 21420% YoY in the quarter but came in above revenue estimates.
  • Reported cash of $220.7 million, providing operational runway into 2029.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)